Literature DB >> 21803090

T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.

Yinon Levy1, Yehuda Flashner, Avital Tidhar, Ayelet Zauberman, Moshe Aftalion, Shirley Lazar, David Gur, Avigdor Shafferman, Emanuelle Mamroud.   

Abstract

Plague, which is initiated by Yersinia pestis infection, is a fatal disease that progresses rapidly and leads to high mortality rates if not treated. Antibiotics are an effective plague therapy, but antibiotic-resistant Y. pestis strains have been reported and therefore alternative countermeasures are needed. In the present study, we assessed the potential of an F1 plus LcrV-based vaccine to provide protection shortly pre- or post-exposure to a lethal Y. pestis infection. Mice vaccinated up to one day before or even several hours after subcutaneous challenge were effectively protected. Mice immunized one or three days pre-challenge were protected even though their anti-F1 and anti-LcrV titers were below detection levels at the day of challenge. Moreover, using B-cell deficient μMT mice, we found that rapidly induced protective immunity requires the integrity of the humoral immune system. Analysis of the individual contributions of vaccine components to protection revealed that rF1 is responsible for the observed rapid antibody-mediated immunity. Applying anti-F1 passive therapy in the mouse model of bubonic plague demonstrated that anti-F1 F(ab')(2) can delay mortality, but it cannot provide long-lasting protection, as do intact anti-F1 molecules. Fc-dependent immune components, such as the complement system and (to a lesser extent) neutrophils, were found to contribute to mouse survival. Interestingly, T cells but not B cells were found to be essential for the recovery of infected animals following passive anti-F1 mediated therapy. These data extend our understanding of the immune mechanisms required for the development of a rapid and effective post-exposure therapy against plague.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21803090     DOI: 10.1016/j.vaccine.2011.07.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.

Authors:  Anthony J Hickey; Jr-Shiuan Lin; Lawrence W Kummer; Frank M Szaba; Debra K Duso; Michael Tighe; Michelle A Parent; Stephen T Smiley
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

2.  Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.

Authors:  Bei Li; Chunhong Du; Lei Zhou; Yujing Bi; Xiaoyi Wang; Li Wen; Zhaobiao Guo; Zhizhong Song; Ruifu Yang
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

Review 3.  Antibody-based vaccine strategies against intracellular pathogens.

Authors:  Arturo Casadevall
Journal:  Curr Opin Immunol       Date:  2018-04-25       Impact factor: 7.486

4.  Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis.

Authors:  Deyan Luo; Jr-Shiuan Lin; Michelle A Parent; Isis Mullarky-Kanevsky; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Michael Tighe; Jim Hill; Andras Gruber; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

Review 5.  Protecting against plague: towards a next-generation vaccine.

Authors:  E D Williamson; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

6.  Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.

Authors:  Anne Derbise; Yuri Hanada; Manal Khalifé; Elisabeth Carniel; Christian E Demeure
Journal:  PLoS Negl Trop Dis       Date:  2015-10-16

7.  Host Iron Nutritional Immunity Induced by a Live Yersinia pestis Vaccine Strain Is Associated with Immediate Protection against Plague.

Authors:  Ayelet Zauberman; Yaron Vagima; Avital Tidhar; Moshe Aftalion; David Gur; Shahar Rotem; Theodor Chitlaru; Yinon Levy; Emanuelle Mamroud
Journal:  Front Cell Infect Microbiol       Date:  2017-06-21       Impact factor: 5.293

8.  Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.

Authors:  Ankit Gupta; Bineet Narayan; Subodh Kumar; Shailendra Kumar Verma
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

9.  Efficacy of primate humoral passive transfer in a murine model of pneumonic plague is mouse strain-dependent.

Authors:  V A Graham; G J Hatch; K R Bewley; K Steeds; A Lansley; S R Bate; S G P Funnell
Journal:  J Immunol Res       Date:  2014-07-06       Impact factor: 4.818

10.  Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague.

Authors:  Yinon Levy; Yaron Vagima; Avital Tidhar; Moshe Aftalion; David Gur; Uri Nili; Theodore Chitlaru; Ayelet Zauberman; Emanuelle Mamroud
Journal:  NPJ Vaccines       Date:  2018-10-19       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.